Telix Pharmaceuticals (TLX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Telix Pharmaceuticals (TLX) is Neutral.

The composite score behind that read is -0.13, weighing +0.10 of bullish evidence against -0.23 bearish.

Telix Pharmaceuticals last closed at $10.88, +3.13% on the session.

Against the IVW growth benchmark the position is +2.21% over the forecast window.

The read is built from 11 underlying insights — 3 bullish and 8 bearish.

Agreement across those insights is 73%.

16 graded predictions for TLX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Telix Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $3.59B.

StockMap tracks Telix Pharmaceuticals as the 61st largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Telix Pharmaceuticals ranks 101st of 344 in the group, against a group median of -0.21.